INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 94,851 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 100,000 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 45,200 | -- | -- |
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 5,146 | -- | -- |
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 194,854 | -- | -- |
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 70,000 | -- | -- |
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 263,000 | -- | -- |
| Jan 03, 2005 |
SVP Fin & Admin, CFO, & Treas
Trans History: 645
|
SVP Fin & Admin, CFO, & Treas | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,800 | -- | -- |
| Oct 15, 2004 |
SVP, Manuf & Process Sciences
Trans History: 109
|
SVP, Manuf & Process Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,000 | -- | -- |
| Oct 08, 2004 |
VP Clinical Programs
Trans History: 37
|
VP Clinical Programs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 3,374 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.